Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance

Launched by TONGJI HOSPITAL · Oct 20, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to monitor patients with hepatocellular carcinoma (HCC), which is a type of liver cancer. Researchers want to see if a specific type of DNA found in the blood, called circulating tumor mitochondrial DNA (ct-mtDNA), can help detect leftover cancer cells after treatment and check for any signs of the cancer returning. This study is currently recruiting participants aged 65 and older who have been diagnosed with HCC and have at least one measurable tumor.

Eligible participants will need to sign a consent form and be able to attend study visits. They should expect to provide blood samples for testing, which will help researchers understand how effective ct-mtDNA is as a monitoring tool for their cancer. It's important to note that individuals with other active cancers or serious complications may not be able to participate. This trial aims to improve the way we track and manage liver cancer, potentially leading to better outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with hepatocellular carcinoma (HCC);
• • Diagnosis of HCC is according to the American Association for the Study of Liver Diseases or European Association for the Study of the Liver guidelines of HCC management;
• • At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or mRESIST criteria.;
• • Expected survival time of 12 weeks or more;
• • Signed informed consent form and ability to comply with the study visits and related procedures as stipulated in the protocol.
• Exclusion Criteria:
• • Patients with other active tumors or severe complications;
• • Insufficient tumor tissue for MRD detection.